229 related articles for article (PubMed ID: 25370416)
21. Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.
Kaeda J; Ringel F; Oberender C; Mills K; Quintarelli C; Pane F; Koschmieder S; Slany R; Schwarzer R; Saglio G; Hemmati P; van Lessen A; Amini L; Gresse M; Vagge E; Burmeister T; Serra A; Carson A; Schwarz M; Westermann J; Jundt F; Dörken B; le Coutre P
Leuk Lymphoma; 2015 Jul; 56(7):2105-13. PubMed ID: 25363400
[TBL] [Abstract][Full Text] [Related]
22. Abnormal centrosome-centriole cycle in chronic myeloid leukaemia?
Patel H; Gordon MY
Br J Haematol; 2009 Aug; 146(4):408-17. PubMed ID: 19563513
[TBL] [Abstract][Full Text] [Related]
23. Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL.
Lin X; Zou X; Wang Z; Fang Q; Chen S; Huang J; Zhe N; Yu M; Zhang Y; Wang J
Oncotarget; 2016 Aug; 7(33):53679-53701. PubMed ID: 27447561
[TBL] [Abstract][Full Text] [Related]
24. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients.
Levescot A; Flamant S; Basbous S; Jacomet F; Féraud O; Anne Bourgeois E; Bonnet ML; Giraud C; Roy L; Barra A; Chomel JC; Turhan A; Guilhot F; Girard JP; Gombert JM; Herbelin A
Cancer Res; 2014 May; 74(10):2669-76. PubMed ID: 24675360
[TBL] [Abstract][Full Text] [Related]
25. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.
Song C; Gowda C; Pan X; Ding Y; Tong Y; Tan BH; Wang H; Muthusami S; Ge Z; Sachdev M; Amin SG; Desai D; Gowda K; Gowda R; Robertson GP; Schjerven H; Muschen M; Payne KJ; Dovat S
Blood; 2015 Oct; 126(15):1813-22. PubMed ID: 26219304
[TBL] [Abstract][Full Text] [Related]
26. Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts.
Theocharides AP; Dobson SM; Laurenti E; Notta F; Voisin V; Cheng PY; Yuan JS; Guidos CJ; Minden MD; Mullighan CG; Torlakovic E; Dick JE
Leukemia; 2015 Jan; 29(1):177-87. PubMed ID: 24791856
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Heaney NB; Pellicano F; Zhang B; Crawford L; Chu S; Kazmi SM; Allan EK; Jorgensen HG; Irvine AE; Bhatia R; Holyoake TL
Blood; 2010 Mar; 115(11):2241-50. PubMed ID: 20068223
[TBL] [Abstract][Full Text] [Related]
28. Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.
Askmyr M; Ågerstam H; Lilljebjörn H; Hansen N; Karlsson C; von Palffy S; Landberg N; Högberg C; Lassen C; Rissler M; Richter J; Ehinger M; Järås M; Fioretos T
Blood Cancer J; 2014 Dec; 4(12):e269. PubMed ID: 25501026
[TBL] [Abstract][Full Text] [Related]
29. Engraftment of chronic myeloid leukemia in SCID mice.
Hoyle CF; Negrin RS
Hematol Oncol; 1998 Sep; 16(3):87-100. PubMed ID: 10235067
[TBL] [Abstract][Full Text] [Related]
30. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.
Frolova O; Benito J; Brooks C; Wang RY; Korchin B; Rowinsky EK; Cortes J; Kantarjian H; Andreeff M; Frankel AE; Konopleva M
Br J Haematol; 2014 Sep; 166(6):862-74. PubMed ID: 24942980
[TBL] [Abstract][Full Text] [Related]
31. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice.
Verstegen MM; Cornelissen JJ; Terpstra W; Wagemaker G; Wognum AW
Leukemia; 1999 Apr; 13(4):618-28. PubMed ID: 10214871
[TBL] [Abstract][Full Text] [Related]
32. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.
Engler JR; Frede A; Saunders VA; Zannettino AC; Hughes TP; White DL
Leukemia; 2010 Apr; 24(4):765-70. PubMed ID: 20147974
[TBL] [Abstract][Full Text] [Related]
33. Forced expression of the Ikaros 6 isoform in human placental blood CD34(+) cells impairs their ability to differentiate toward the B-lymphoid lineage.
Tonnelle C; Bardin F; Maroc C; Imbert AM; Campa F; Dalloul A; Schmitt C; Chabannon C
Blood; 2001 Nov; 98(9):2673-80. PubMed ID: 11675337
[TBL] [Abstract][Full Text] [Related]
34. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment.
Quintás-Cardama A; Qiu YH; Post SM; Zhang Y; Creighton CJ; Cortes J; Kornblau SM
Cancer; 2012 Nov; 118(21):5283-92. PubMed ID: 22517119
[TBL] [Abstract][Full Text] [Related]
35. Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.
Madapura HS; Nagy N; Ujvari D; Kallas T; Kröhnke MCL; Amu S; Björkholm M; Stenke L; Mandal PK; McMurray JS; Keszei M; Westerberg LS; Cheng H; Xue F; Klein G; Klein E; Salamon D
Oncogene; 2017 Aug; 36(32):4619-4628. PubMed ID: 28368400
[TBL] [Abstract][Full Text] [Related]
36. Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia.
Van den Berg D; Wessman M; Murray L; Tong J; Chen B; Chen S; Simonetti D; King J; Yamasaki G; DiGiusto R; Gearing D; Reading C
Blood; 1996 May; 87(10):4348-57. PubMed ID: 8639795
[TBL] [Abstract][Full Text] [Related]
37. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.
Warsch W; Grundschober E; Berger A; Gille L; Cerny-Reiterer S; Tigan AS; Hoelbl-Kovacic A; Valent P; Moriggl R; Sexl V
Oncotarget; 2012 Dec; 3(12):1669-87. PubMed ID: 23458731
[TBL] [Abstract][Full Text] [Related]
38. Studies of P-glycoprotein in chronic myelogenous leukaemia patients: expression, activity and correlations with CD34 antigen.
Turkina AG; Baryshnikov AY; Sedyakhina NP; Folomeshkina SV; Sokolova MA; Choroshco ND; Stavrovskaya AA
Br J Haematol; 1996 Jan; 92(1):88-96. PubMed ID: 8562416
[TBL] [Abstract][Full Text] [Related]
39. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
40. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
